Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

This study tests a combination of immunotherapy (camrelizumab), chemotherapy, and endoscopic surgery for people with nasopharyngeal carcinoma (cancer at the back of the nose) that has come back after initial treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with recurrent nasopharyngeal carcinoma confirmed by biopsy - Your cancer can be surgically removed (specific tumor stages apply) - Your cancer came back at least 6 months after your first radiation treatment - You have no distant spread (metastasis) of the cancer - You have no recent risk of severe bleeding **You may NOT be eligible if...** - Your cancer has spread to distant parts of the body - Your cancer recurred less than 6 months after initial radiation - Your tumor is too advanced to be surgically removed - You have severe heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.